High-throughput 3D phenotypic screening identifies repurposed MEK inhibitors as drivers of chondrogenesis for cartilage regeneration
These findings support the potential of MEK inhibitors like Trametinib, and other selected bioactive compounds, as promising agents for cartilage regeneration. Their repurposing could offer innovative therapeutic strategies for treating cartilage-related disorders, including osteoarthritis.
Authors
- Alicia J. El Haj (ORCID: https://orcid.org/0000-0003-3544-5678)
- Jacob Richard Ballard
- Hadi Hajiali (ORCID: https://orcid.org/0000-0002-2100-9632)
- Neil O. Carragher (ORCID: https://orcid.org/0000-0001-5541-9747)
- Kerime Ebrar Okur
- Richard Elliott
- Justyna Cholewa-Waclaw
Institutions
- Edinburgh Cancer Research (GB)
- MRC Centre for Regenerative Medicine (GB)
- NIHR Birmingham Biomedical Research Centre (GB)
- University of Edinburgh (GB)
Publication Details
- Journal
- Frontiers in Bioengineering and Biotechnology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.3389/fbioe.2026.1748443
- Primary Topic
- Osteoarthritis Treatment and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- UK Regenerative Medicine Platform
- Medical Research Council
- Birmingham Biomedical Research Centre